Karyopharm Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Karyopharm Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2014 to Q3 2024.
  • Karyopharm Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$32.1M, a 7.05% increase year-over-year.
  • Karyopharm Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$87.5M, a 37.4% increase year-over-year.
  • Karyopharm Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$143M, a 13.4% increase from 2022.
  • Karyopharm Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$165M, a 33.2% decline from 2021.
  • Karyopharm Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$124M, a 36.8% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$87.5M -$32.1M +$2.43M +7.05% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 -$89.9M $23.8M +$56.4M Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 -$146M -$37.4M -$3.24M -9.48% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$143M -$41.8M -$3.33M -8.65% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-29
Q3 2023 -$140M -$34.5M +$1.82M +5.01% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$142M -$32.6M +$16.4M +33.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 -$158M -$34.1M +$7.27M +17.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$165M -$38.5M -$77.2M -199% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-29
Q3 2022 -$88.1M -$36.3M +$15.5M +29.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$104M -$49.1M +$4.52M +8.44% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$108M -$41.4M +$16M +27.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 -$124M $38.7M +$82.1M Oct 1, 2021 Dec 31, 2021 10-K 2024-02-29
Q3 2021 -$206M -$51.8M +$1.68M +3.15% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$208M -$53.6M -$7.16M -15.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$201M -$57.4M -$4.48M -8.47% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$196M -$43.4M +$5.23M +10.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-17
Q3 2020 -$201M -$53.5M -$12.1M -29.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 -$189M -$46.4M -$3.01M -6.94% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$186M -$52.9M +$13.2M +20% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$200M -$48.6M +$9.56M +16.4% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 -$209M -$41.4M +$6.72M +14% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 -$216M -$43.4M -$9.76M -29% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$206M -$66.2M -$27.7M -72% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 -$178M -$58.2M -$19.2M -49.1% Oct 1, 2018 Dec 31, 2018 10-K 2019-02-28
Q3 2018 -$159M -$48.1M -$17.4M -56.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 -$142M -$33.7M -$4.27M -14.5% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$138M -$38.5M -$8.54M -28.6% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q4 2017 -$129M -$39M -$12.1M -44.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-28
Q3 2017 -$117M -$30.6M -$5.22M -20.5% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-28
Q2 2017 -$112M -$29.4M +$771K +2.56% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-28
Q1 2017 -$112M -$29.9M -$2.86M -10.6% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-28
Q4 2016 -$110M -$26.9M +$2.11M +7.27% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-15
Q3 2016 -$112M -$25.4M +$4.95M +16.3% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-15
Q2 2016 -$117M -$30.2M +$2.54M +7.76% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-15
Q1 2016 -$119M -$27.1M -$992K -3.81% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-15
Q4 2015 -$118M -$29M -$3.12M -12% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-16
Q3 2015 -$115M -$30.4M -$10.6M -54% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-16
Q2 2015 -$104M -$32.7M -$16.3M -99% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-16
Q1 2015 -$88.2M -$26.1M -$12.4M -90.4% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-16
Q4 2014 -$75.8M -$25.9M Oct 1, 2014 Dec 31, 2014 10-K 2016-03-15
Q3 2014 -$19.7M Jul 1, 2014 Sep 30, 2014 10-K 2016-03-15
Q2 2014 -$16.4M Apr 1, 2014 Jun 30, 2014 10-K 2016-03-15
Q1 2014 -$13.7M Jan 1, 2014 Mar 31, 2014 10-K 2016-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.